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Abstract
Advances in genomic technology and an increase in the number of gene-disease
associations have helped reduce the number of individuals living without a diagnosis.
Whole exome sequencing (WES) analyzes the entire human exome in an attempt to
determine if there is a molecular etiology for individuals who remain undiagnosed after
other clinical or molecular investigations. Still, WES leaves most individuals
undiagnosed, resulting in feelings of disappointment and uncertainty. Individuals who
remain undiagnosed after WES can subsequently undergo WES reanalysis later due to
improvements in bioinformatics, software updates, and an increase in known genedisease associations. This is the first study, to the investigator’s knowledge, which
investigates parental perspective of those undergoing the most current genetic testing
available. This study recruited parents of undiagnosed individuals who have completed
WES and subsequent reanalysis through the Greenwood Genetic Center to investigate
their response to and experience with WES reanalysis while on their diagnostic odyssey.
Six semi-structured interviews were conducted, recorded, and transcribed verbatim.
Transcripts were analyzed using grounded theory and assigned codes to meaningful
segments of text. Results showed most participants had lower expectations of reanalysis
compared to the initial WES and felt it would not lead to a diagnosis. Most participants
responded to nondiagnostic reanalysis results with feelings of disappointment and worry
about the future. However, some exhibited a difference in the degree to which they
negatively responded. Most participants recognized that reanalysis has been unhelpful for
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their child but expressed willingness to contribute to science if it will assist future
individuals on a diagnostic odyssey. Despite feelings that reanalysis was unhelpful, most
participants would consider reanalysis again for their child. Considering the apparent
comprehensive nature of genomic testing, these results show there is a need to balance
hope and realistic expectations during counseling and consent of WES reanalysis. In
addition, parents desired ongoing medical support which can be offered through
reanalysis.
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Chapter 1: Background
1.1 A diagnosis
The journey and search for a diagnosis is referred to in the clinic and literature as
a “diagnostic odyssey.” The process of a diagnostic odyssey has been defined as “the
time between when a parent or provider first becomes concerned about a child’s
development and a diagnosis is eventually reached” (Carmichael, Tsipis, Windmueller,
Mandel, & Estrella, 2015). All individuals who have received a diagnosis have been on
varying lengths of a diagnostic odyssey. For some, their diagnostic odyssey may last for
months or years while others may remain undiagnosed in their lifetime.
There are many different times during the lifespan when an individual can be
diagnosed. The earliest time one might receive a diagnosis is prenatally. For example, a
diagnosis of Down syndrome can be made during the first trimester of pregnancy through
a procedure known as chorionic villus sampling (CVS). Using the tissue obtained through
CVS, a chromosomal karyotype is completed to assess the baby’s number of
chromosomes.
Postnatally the pursuit of a diagnosis begins with clinical recognition and
evaluation of an individual’s symptoms. If a condition is not readily suspected or
diagnosed, an individual may spend time as an in- or out-patient, undergoing various
imaging, clinical or laboratory tests, and consults with experts. In general, individuals
who undergo a diagnostic odyssey have unexplained, medically complex features.
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In the new age of technology, many will undergo genetic testing as part of their
diagnostic odyssey. Genetic testing can help clarify a clinical diagnosis or give an
individual a molecular diagnosis when a clinical diagnosis is unclear. A molecular
diagnosis means that the diagnosis has a known biological cause that can be tested. This
is different from a clinical diagnosis which describes physical features but the diagnosis
does not necessarily have a known biological cause that can be molecularly detected.
Typically, to make a clinical diagnosis there are standardized criterion that must be met
and published guidelines that are followed (Makela, Birch, Friedman, & Marra, 2009).
When a molecular and clinical diagnosis has been thoroughly researched, the medical
field has prognostic and anticipatory information to guide the family and dictate
treatment. Although some molecular diagnoses may be well researched, many can be rare
or newly discovered and, therefore, not have as much clinical information available.
A third type of diagnosis is known as a “working diagnosis.” A working diagnosis
is used when a clinical or molecular diagnosis has not been confirmed, but there may be
suspicion of a condition (Lewis, Skirton, & Jones, 2010). Even though a condition has
not been confirmed, a working diagnosis can be beneficial because the individual may
have the ability to obtain services and access to support groups (Lenhard, Breitenbach,
Ebert, Schindelhauer-Deutscher, & Henn, 2005).
1.2 The impact of a diagnosis
Receiving a diagnosis can help provide families with emotional, medical, and
educational benefits. Many studies have found that a diagnosis can give a family a sense
of closure, help guide family planning, and provide the recurrence risk in future children
(Carmichael et al., 2015; Lenhard et al., 2005; Graungaard & Skov, 2007). An additional

2

benefit of receiving a diagnosis includes improving the psychosocial outcomes for
individuals and families affected by disabilities (Rosenbaum, 1988). Moeschler and
Shevell (2014) explain the effect of receiving a diagnosis as a “healing touch” that
bolsters well-being. Carmichael and colleagues (2015) found that receiving a diagnosis
lifted some of the emotional burden associated with being undiagnosed. Emotional
burden was lessened because a diagnosis validated parental concerns, justified their
pursuit of a diagnosis, gave them access to certain support groups, and allowed them to
properly plan for the future.
How an individual receives a diagnosis affects satisfaction with the medical field.
A qualitative study interviewing parents of physically and mentally disabled children
who recently received a diagnosis found that the process of receiving a diagnosis and the
certainty of the stated diagnosis strongly influenced the parents’ experiences and abilities
to cope with a diagnosis. Themes that influenced satisfaction with the diagnostic process
depends on the context. This includes the setting of where the information was given, the
timing of the information, and level of information related to the parents’ readiness to
receive the information (Graungaard & Skov, 2007). These results showed that there are
many variables that influence a diagnostic odyssey, making it a complex time for
families.
The diagnosis of a rare condition may happen years after symptoms appear and
many tests later. The natural history, prognosis or medical management of rare conditions
may not be known. Some families prefer a diagnosis, even if it involves a poor prognosis,
rather than remain uncertain (Makela et al., 2009; Stewart & Mishel, 2000). In addition to
preferring a diagnosis rather than not, many parents understand that receiving a specific
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diagnosis may not change medical management or have a known cure. Notably, these
parents recognized the importance of their child’s test results for future medical research
(Rosenthal, Biesecker, & Biesecker, 2001).
1.3 Living without a diagnosis
Unfortunately, some may never have an end to their diagnostic odyssey. One
study found between 30 and 50% of individuals with intellectual disability go without a
known etiology (Daily, Ardinger, & Holmes, 2000). According to The Rare and
Undiagnosed Network (2017), one in ten individuals are living with a rare or
undiagnosed disease; half of these individuals are children.
Living without a diagnosis can be challenging and have various adverse effects
for individuals and their families. Effects may include the inability to receive certain
medical or educational services provided and covered by insurance or the state. In
addition, living with an undiagnosed condition may involve a lack of direct treatment,
anticipatory guidance, and information on prognosis (Carmichael et al., 2015; Lewis et al.
2010). One study found that families may feel emotionally isolated, unable to connect
with others living with a similar diagnosis, and have difficulty in coping with an
uncertain future (Graungaard & Skov, 2007). Overall, many studies have repeatedly
reported time spent undiagnosed as stressful, overwhelming, and involving various
negative emotions. This is a result of added medical care for their child and required
medical appointments. Additionally, feelings of being out of control may result in
emotional distress and burden (Lewis et al., 2010).
Those on a diagnostic odyssey spend much of their time wondering how to plan
and manage medical concerns (Rosenthal et al., 2001). A recent study investigated
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uncertainty and lack of control in parents of children living with various medical
conditions, some of which were undiagnosed. Lower levels of optimism and higher levels
of uncertainty were reported in individuals who perceived less control over their child’s
undiagnosed condition. Although parents felt they did not have control overall, they felt
in control of some aspects of their child’s condition. The aspects they felt they could
control included information and decision making, advocacy, the child’s comfort, and
self-care (Madeo, O’Brien, Bernhardt, & Biesecker, 2012).
The emotional burden associated with being undiagnosed shows the importance
of establishing a strong support system for these individuals and their families as they
search for a diagnosis. Although they may not have direct access to certain medical or
support services, there are a handful of online support groups created specifically for
those who are undiagnosed or diagnosed with rare conditions. One online support group,
Syndromes Without a Name (SWAN), is nationally available and officially became a
nonprofit organization in the United States in 2006. The site allows families facing
similar challenges to connect either through the SWAN website or Facebook group. A
few goals of the group are to address the lack of information associated with being
undiagnosed, offer emotional support, and help with psychosocial concerns such as
isolation, guilt, or helplessness (Syndrome Without a Name, 2017).
A second online support group known as the Rare & Undiagnosed Network
(RUN) aims to address similar issues. Their mission is to “empower rare and
undiagnosed patients and their families with genomic information through community,
advocacy, networking, and support” (Rare and Undiagnosed Network, 2017). Like
SWAN, families can share their stories, and RUN helps give them a sense of community.
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These two organizations are wonderful resources for families on a diagnostic odyssey and
dealing with uncertainty surrounding their child’s health.
Not only is a diagnostic odyssey emotionally exhausting, but it is financially
costly as well. The cost of discovering a diagnosis may include more expensive, largescale genomic sequencing that is recommended as second-tier testing completed after
cheaper and targeted testing is negative. Genomic testing is broad, nonspecific testing
that looks at a much larger part of the human genome than targeted genetic testing. A
recent study found that patients who had previously completed basic and complex
investigations searching for a diagnosis could be spending up to $21,000 (Stark et al.,
2017). In this study “basic investigations” referred to standard clinical assessments
including biochemical, imaging, and neurophysiological studies while “complex
investigations” referred to non-standard testing that may have included complex
biochemical or genetic testing.
1.4 New technologies and genomic sequencing
In recent years, major medical strides and technological advancements have
worked towards decreasing the number of undiagnosed individuals and increasing
knowledge of rare conditions. To aid in diagnosing medically complex cases, the
Undiagnosed Diseases Network (UDN) was created in 2008. The UDN is a multisystem
research study funded by the Nation Institute of Health (NIH) known as the NIH
Undiagnosed Disease Program (UDP). The purpose of the UDP is to gather clinical and
research specialists working in the U.S. with the common goal to solve medical mysteries
using new technology (Gahl, Wise, & Ashley, 2015). Thirteen research and clinical sites
contribute to the UDP including Duke Medicine, Harvard Teaching Hospital, Stanford
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Medicine, and Vanderbilt University Medical Center (Undiagnosed Diseases Network,
2017). These centers collaborate with each other and their patients to understand better
the origins of disease. By publishing their work, the UDN is making great efforts to
improve the level of diagnostics and care in hopes to relieve some of the burden felt by
individuals and parents of those living with undiagnosed conditions.
Since the publication of the completed human genome sequence in 2004, decrease
in the cost of sequencing DNA has changed the landscape of clinical testing and is a
driving force behind changes in genetic testing practice guidelines (International Human
Genome Sequencing Consortium, 2004). The initial sequencing of the human genome
utilized a technique known as Sanger sequencing. Although Sanger sequencing still is
used, most laboratories now heavily rely on a more recently developed sequencing
technique known as Next Generation Sequencing (NGS). NGS allows for rapid
sequencing of single and multiple genes at a reduced cost and faster turnaround time
(TAT) compared to traditional Sanger sequencing (Mardis, 2008). The first commercially
available NGS sequencer, known as the 454 Life Sciences Next Generation Sequencing
system, was launched in 2005 (Van Dijk, Auger, Jaszczyszyn, & Thermes, 2014). Since
then, data output has more than doubled each year and the cost of genomic sequencing
has decreased at a rate faster than anticipated by Moore’s Law. Since the cost of genomic
sequencing is decreasing more quickly than anticipated, its clinical use is becoming more
accessible (Sarda & Hannenhalli, 2014).
When DNA sequencing first was offered, clinical testing was limited to a single
gene or small collection of genes. A gene is a unit of genetic material that provides the
instructions for our bodies. Genes are housed within the human genome. Available
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testing has expanded to include multi-gene tests, known as panels. Panel testing targets
specific genes that are indicated when clinical evaluation suggests a diagnosis. Panels can
be thought of as “first-tier” testing because they are the most clinically efficient in terms
of cost and diagnostic yield.
Genetic technology now has allowed the ability to clinically offer analysis of an
individual’s entire genome. The entire human genome consists of approximately 20,000
genes and therefore, encompasses a complete set of DNA (Ezkurdia et al., 2014).
Genomic sequencing is currently recommended when clinical evaluation is unclear or
uncertain, the genes involved are generally unknown, the patient has tested negative
using other first-tier testing options, or a broader testing approach is warranted. These
broader approaches can include whole genome sequencing (WGS) or whole exome
sequencing (WES).
Whole genome sequencing and WES are sequencing techniques that use NGS
technologies. Rare or unexpected diagnoses often are revealed by WGS and WES, which
sequence the entire human genome and exome, respectively. The Human Genome Project
found that the human genome contains a total of about three billion base pairs. The
human exome is the portion of the human genome which codes for proteins made within
the body and accounts for less than one percent of the genome (International Human
Genome Sequencing Consortium, 2004). This estimates the human exome to
approximately 60 million base pairs split across about 180,000 exons (Ng et al., 2009).
1.5 Whole exome sequencing
Laboratory procedure involved in genomic sequencing is complex. In simplified
steps, WES involves the lab’s receipt of the patient’s specimen, usually a blood sample,
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followed by DNA extraction. The exome then is targeted, enriched, and sequenced by
NGS (White et al., 2017). One of the more complex, and last steps is variant
classification and annotation. In previous years, variant classification and annotation
encompassed a significant amount of WES result analysis. In 2014, it was estimated that
20 to 40 hours of expert time was needed to analyze a clinical exome (Dewey et al.,
2014). Recent improvements in bioinformatics tools, updated analysis software, and new
public variant databases have drastically reduced the time spent analyzing genomic data
(Stenson et al., 2017; Wright et al., 2018).
Variant analysis involves filtering through and deciphering which detected
variant(s) best matches with the patient’s clinical features, or phenotype. In this way,
WES and WGS results are phenotypic-driven. This means that labs will report variants
that potentially explain what is clinically indicated. For example, if a patient presents
with many unexplained features such as seizures, low muscle tone, strabismus, and a
congenital heart defect, only variants associated with any of those features are reported.
To help standardize variant classification, the American College of Medical
Genetics and Genomics (ACMG) in collaboration with the Association for Molecular
Pathology (AMP) has published standards and guidelines on variant classification and
interpretation that laboratories can use when analyzing genomic data. A variant must
meet certain criterion to be correctly classified. Included in the criterion are specific
variant evidence such as population data, computational (in silico) data, functional data,
symptomatic data, etc. The five standard categories of variants detected by WES include
‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’.
A variant is classified as pathogenic or likely pathogenic when evidence suggests the
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change is causative of the patient’s features. A variant of uncertain significance is
classified as a change for which there is not enough data to support its classification as
likely pathogenic or likely benign. Finally, the classification of likely benign or benign is
justified when evidence indicates the change is not disease-causing (Richards, Aziz, Bale,
Das, & Gastier-Foster, 2015).
Based on the laboratories’ classification of variants detected, laboratories will
then classify genomic test results into four categories. Result classification is separate
from variant classification but is influenced by the type of variant detected. The first type
of result is a positive, or definitive result, meaning the lab found a pathogenic or likely
pathogenic variant in the patient resulting in a molecular diagnosis. The second result is a
possible, or probable diagnosis. This means the lab detected a variant that is located in a
known disease-causing gene possibly associated with the patient’s clinical features. A
third result is a variant in a new ‘candidate gene’ not previously associated with human
disease but suspected to be disease-causing based on the nature of the variant and the
known function of the gene product. The final type of result is a negative result meaning
the lab found no variant associated with disease or the phenotype of the patient
(Williams, Retterer, Cho, Richard, & Juusola, 2016). This final result leaves the patient
undiagnosed.
1.6 Clinical implementation of whole exome sequencing
Genetic testing is currently at a turning point with the advent of genomic
sequencing. Although the cost of DNA sequencing is decreasing, interpretation of
genomic sequencing data continues to become more complex and time-consuming due to
the large amount of data generated. Whole genome sequencing of a single sample
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generates about 3 million variants that are different from the human reference genome
while WES generates a range of 30,000 to 70,000 variants per sample (Hedge et al.,
2017). Although WGS can be ordered clinically, it is not utilized as frequently as WES
because it is more expensive and results in a greater amount of data that requires much
more analysis and interpretation than WES.
There have been several publications addressing the clinical utility and
implementation of WES. Challenges identified in clinical implementation include cost,
TAT, lack of clinical guidance, variant interpretation, and potential incidental findings
(Bertier, Hetu & Joly, 2016; Iglesias et al., 2014; Williams, Cashion, & Veenstra, 2015).
There has only been one publication suggesting comprehensive guidelines for the
implementation of exome sequencing in the clinic (Matthijs et al., 2015).
Recently, studies have investigated the utility of clinically offering WES as firsttier testing (Krabbenborg et al., 2016; Stark et al., 2016; Tan et al., 2017). A 2015 study
compared three different tests which utilized Next Generation Sequencing (NGS). Sun
and colleagues (2015) used nine samples to investigate the differences between gene
panels, WES, and WGS data from patients with intellectual disability. The study looked
at 537 gene panels targeted toward intellectual disability. The largest limitation of panel
testing is that they are targeted and only successful if the causative gene is on the panel.
Interestingly, WES did not miss any of the variants detected by the more comprehensive
WGS. Although they recognized that panel testing is the cheapest and WGS is technically
the most inclusive test, they concluded that WES was the best test option when clinical
indication involves intellectual disability. WES analyzes more genomic material and will
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find variants in genes not included on targeted panels. WES is a reasonable alternative to
WGS due to cost, TAT, and ability to clinically implement the tests.
The economic cost of WES has been a large challenge for clinical
implementation. When WES first was offered in 2011 the cost ranged between $4,500
and $9,000 (Atwal et al., 2014). Since then, the cost of WES has decreased. Stark and
colleagues (2017) investigated the cost effectiveness of WES and quoted the cost of a
clinical WES as approximately $2,412. A review of articles published between 2014 and
2015 found that the cost of WES was thought to be too expensive for use as standard
testing (Bertier et al., 2016).
In addition to cost, the length of time waiting for results is an important aspect of
WES. In 2014, the TAT for WES ranged from 11 to 21 weeks with an average of 18
weeks (Atwal et al., 2014). Since 2014, TAT has substantially decreased in 2017 to an
average of 40 days in cases where individuals needed results quickly (Bourchany et al.,
2017). The high cost and lengthy TAT is due partly to the process and analysis of WES
variants detected by the laboratory.
Practical concerns regarding patient education and consent in pretest counseling
are a barrier to clinically offering WES (Iglesias et al., 2014). Due to the vast amount of
data analyzed in WES, pre-test counseling can be extensive. In many clinics, a genetic
counselor is the medical professional working with these families. Patients and families
pursuing WES should be counseled on many aspects including TAT, possible results,
yield of testing, insurance coverage, cost, updates of test results or reanalysis, and impact
on clinical care. A recent study found that parents were able to accurately describe their
child’s WES results and communicate the implications (Tolusso et al., 2016). This shows
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that genetic counseling in that study had provided appropriate informed consent and
follow-up for WES despite its complexity.
Another important aspect lending to the challenges of offering clinical genomic
testing is the possibility of incidental or secondary findings. Guidelines introduced by the
ACMG in response to challenges associated with incidental findings (Green et al., 2013
& Kalia et al., 2017). Incidental findings pertain to results discovered after completion of
filtering and segregation analysis but are not related to the primary indication for testing.
Secondary findings pertain to results not related to the primary indication but that are
sought purposely during the analysis of the test results (Weiner, 2014). Importantly, both
incidental and secondary findings may have health, reproductive, or personal importance
for the patient or the family. Different from incidental findings, secondary findings are
sought because they are medically actionable and have published health management
guidelines. More time may be spent informing patients about the possibility of secondary
findings since these results may be more medically actionable than other variants
detected (Tolusso et al., 2016).
The ACMG Working Group published a secondary findings list of 59 genes and
26 conditions that clinical laboratories have an obligation to test for during the course of
WES and WGS (Green et al., 2013; Kalia et al., 2017). The list includes childhood- and
adult-onset conditions such as Li-Fraumeni syndrome, PTEN hamartoma tumor
syndrome, Hereditary Breast and Ovarian Cancer syndrome, and Marfan syndrome.
Certain variants found in any of these conditions should be reported by the laboratory,
regardless of the indication for testing. This is grounded in the duty to prevent harm by
warning patients and their families about medically actionable information. There is
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controversy surrounding this aspect of genomic testing and if the duty to report these
findings supersedes patient or parent autonomy. On the other hand, health providers may
be liable if they fail to report secondary or incidental findings that could have prevented
disease or changed medical management. In 2014, ACMG revised recommendations to
state that patients should be given the option to opt-out before the testing takes place.
That way the patients do not receive results that they did not desire (Clayton et al., 2013).
1.7 Diagnostic yield of whole exome sequencing
Large scale studies and laboratory data show that WES can find a disease-causing
pathogenic variation in approximately 25-40% of individuals, leaving up to 75% of
individuals pursuing WES undiagnosed after completion (Baldridge et al., 2017; Farwell
et al., 2014; Lee et al., 2014; Yang et al., 2014). Farwell and colleagues (2014) found the
highest diagnostic rates were observed among patients with ataxia (44%), multiple
congenital anomalies (36%), and epilepsy (35%).
Because WES does not yield a diagnosis for patients in up to 75% of cases, the
limitations of WES and its inability to detect causative genetic variants in severely
affected individuals is important to understand. In general, WES sequences exons and
short exon-flanking regions, including consensus splice-site sequences (Hedge et al.,
2017). The test will not detect genetic changes located outside of these regions. This
includes non-protein coding regions such as introns, variants located in regulatory units,
transcriptional units or mitochondrial DNA. Alterations that do not affect the sequence of
the DNA, such as chromosomal rearrangements, inversions, trinucleotide repeats, or
epigenetic changes will not be detected as well (Need & Goldstein, 2016).
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Labs often analyze WES as “trios”, which includes sequencing three samples; the
patient’s and both biological parents’ samples, or the patient’s and two other closely
related relatives’ samples. The lab can then compare the patient’s findings to their
biological parents or other relative. Although not essential, a trio allows for the lab to
determine if the variant is de novo, or not inherited from either parent. The diagnostic rate
of WES when run as a trio has been reported as 37%, specifically done on the patient and
two first-degree relatives. This was compared with a singleton WES diagnostic rate of
21% (Farwell et al., 2014).
Importantly, having both parental samples may allow for the detection of certain
genetic alterations such as uniparental disomy (UPD). Uniparental disomy is an atypical
situation where a child has two copies of the same chromosome from one parent, as
opposed to the expected one from each parent (Bis et al., 2017). When both parental
samples are not available, WES would not be able to detect UPD.
Another reason WES may not detect a causative variant involves lab processes.
Differences in laboratory bioinformatics, variant filtration techniques and, despite
standardized guidelines, the definition of a pathogenic variant may all impact detection
and yield. The laboratory will analyze all variants found in a patient through its own
filtration system to determine which variant best matches the patient’s phenotype. If a
variant is unassociated with the clinical indications, the variant may not be reported. It is
possible some novel, yet causative, variants go unreported since WES results are
phenotypic-driven. In addition, depending on the variant’s classification (i.e. pathogenic,
benign, etc.) the result may or may not give the patient a straight forward diagnosis or
answer. For example, a variant found in a potential candidate gene, for a new genetic
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condition, will likely have little known data and have little impact on clinical care (Lee et
al., 2014).
Additional components that affect WES diagnostic yield include data mining,
gene discovery, newly available clinical information, and increasing collaborations
between laboratories, clinicians and researchers (Wenger, Guturu, Bernstein, & Bejerano,
2017; Wright et al., 2018). Data mining refers to the process whereby laboratories sift
through literature and research any new or helpful information on the detected variant.
Data mining may also include searching for previously reported genetic variants using
databases such as ClinVar (ncbi.nlm.nih.gov/clinvar), GeneMatcher (genematcher.org)
and PhenomeCentral (phenomecentral.org). These sites match laboratories and institutes
with one another when they both have identified individuals with a variant in the same
gene, and with matching clinical features. Knowledge of other labs and individuals with
the same rare variant can help the healthcare providers to properly explain the variant to
the patient. Furthermore, finding others who have seen the same variants can aid in
classifying a variant.
Genomic sequencing has lent itself to the revelation of new disease phenotypes
but has also resulted in producing diagnostic dilemmas caused by genes previously
unknown to cause human disease. Resources such as GeneMatcher and PhenomeCentral
have likely helped establish some of these gene-disease associations in combination with
new technology, such as WGS and WES. As White and colleagues (2017) conclude, the
field must “...share data, clinical findings, and experiences...” to successfully implement
an influential tool such as genomic sequencing.
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It is evident that such rapidly evolving genetic research and sharing would have a
strong impact on the diagnostic yield of WES. As of 2014, 23% of positive WES results
were found within genes characterized since 2012 (Farwell et al., 2014). In October of
2004 a database of human genes and genetic disorders and traits, known as the Online
Mendelian Inheritance in Man (OMIM), listed 1,636 phenotypes with a known molecular
cause. Eleven years later in October of 2015, OMIM listed 4,570 Mendelian disorders
with gene-disease associations. This was an increase of about 266 entries per year over
the past eleven years (Wenger, Guturu, Bernstein, & Bejerano, 2017).
1.8 Whole exome sequencing and reanalysis
Although use of genomic testing has helped expand clinical genetics, this is often
not the final chapter in a patient’s diagnostic odyssey. For those patients who do not
receive a diagnosis from initial WES testing, reanalysis of results may be an option.
Reanalysis is accomplished not by obtaining a second blood sample, but by reexamining
the initial variants found through a lab’s analysis bioinformatics system. Although there
are published ACMG guidelines on variant classification in WES, there are currently no
published guidelines on WES reanalysis.
Given the fast pace of gene discovery, it is important to realize the need to
thoroughly reanalyze WES results (Zhu et al., 2015). One rationale behind a
reexamination of the same data after a significant amount of time has passed is that the
number of gene-disease associations has improved and thus the likelihood of identifying
a causative variant is increased. Other factors that allow for reanalysis include
improvement to lab bioinformatics and changes in variant annotation over time. As
variant databases grow, laboratories have the ability to update reports and variant
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classifications. According to the published ACMG guidelines on the interpretation of
sequence variants, previous variant classifications may require modification due to
increasing population data (Richards et al., 2015). In some cases, variants previously
classified as ‘uncertain significance’ may now have enough supportive evidence to be reclassified as either ‘benign’ or ‘pathogenic’.
The increasing yearly rate of gene-disease discovery and increasing size of variant
databases in combination with recently published WES reanalysis data has validated the
usefulness of reanalysis for those who have not received a diagnosis from their initial
WES results. Given that WES was first clinically offered in 2011, various laboratories
and studies have only recently reported reanalysis diagnostic yield. According to one
study, reanalysis of 40 WES data at a two to three-year interval could result in a 10%
reanalysis diagnostic yield (Wenger et al., 2017). More recently, Ewans and colleagues
(2018) found that reanalysis 12 months following initial WES results could have an 11%
diagnostic yield in patients with Mendelian disorders, bringing their study of 54
participants’ diagnostic yield from 30 to 41%. Another large-scale study completed in the
United Kingdom reanalyzed 1,133 WES data finding a 13% reanalysis diagnostic yield
(Wright et al, 2018). This means that up to 13% of families who did not receive a
diagnostic result from their initial WES subsequently could receive a diagnostic result
from reanalysis at least one year after the initial WES.
1.9 Parental experience with whole exome sequencing
As previously mentioned, WES is indicated in cases of undiagnosed, medically
complex individuals whose medical condition has not been identified through previous
clinical or molecular investigations. The Undiagnosed Disease Network of the National
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Institute of Health stated that “[Undiagnosed] patients have often spent years visiting
medical centers and healthcare providers in different specialties across the country,
accumulating large amounts of medical notes and test results, often at great emotional
and financial cost” (Gahl et al., 2015).
There have been several studies investigating the psychosocial effects of WES.
Rosell and colleagues (2016) found that parents view the process of WES as a positive
experience resulting in feelings of altruism and hope. In addition, the study found parents
may feel a sense of duty to pursue WES to find a diagnosis, and the test can consequently
influence medical care and reduce worry. Unfortunately, a positive result from WES or
reanalysis may not provide information that may benefit a patient and their family. It is
likely that if a causative variant is found from reanalysis of WES results, the condition is
either extremely rare or newly discovered, leaving the family with a sense of isolation
and frustration (Graungaard & Skov, 2007).
On the other hand, the comprehensive nature of WES may give families false
hope and cause feelings of disappointment following nondiagnostic results (Brett et al.,
2018). The dichotomy of emotions before versus after testing calls for a balance between
hope and realistic expectations. Krabbenborg and colleagues (2016) found that WES
results were associated with relief as well as worry, independent of the test result. When
families received a conclusive diagnostic WES result, parents reported becoming more
accepting, more informed on caring for their child, and better able to cope with perceived
guilt. On the other hand, parents identified loss of hope in the recovery of their affected
child and loss of social support surrounding the “new label”. Some parents felt they no
longer belonged to patient organizations they previously participated in. Although some
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felt a renewed sense of isolation, many were enabled to search for information regarding
the child’s conclusive diagnosis, given by WES. While searching, many would come
across blogs or Facebook pages and were able to establish new relationships with peers
(Krabbenborg et al., 2016).
Although many studies have looked at patient understanding and perception of
initial WES, none to the researcher’s knowledge, have specifically assessed family
response to and understanding of WES reanalysis. Based on the complex and differing
perspectives of families living with undiagnosed conditions, it is essential to survey this
population to shape current clinical practices and patient experience. In addition, it is
important to identify gaps in knowledge and needed areas of growth in current practice
when offering WES reanalysis. It is expected that WES reanalysis will continue as
genomic testing becomes more accessible and as more information is gained.
This population is unique and most have already completed previous genetic
testing. Given that the initial WES process has been found to provide families hope, it
was expected that WES reanalysis will yield a similar expectations of reanalysis. Also, it
was expected that families will experience negative emotions following nondiagnostic
reanalysis results. Those who had received a diagnosis from WES were expected to have
had a more positive response to the testing than those who remained undiagnosed. The
expected dichotomy of emotions before versus after testing provides an essential need to
assess how to best counsel these individuals and families pursuing WES reanalysis.
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Chapter 2: Parental experience with whole exome sequencing reanalysis and
its impact on the diagnostic odyssey1
2.1 Abstract
Advances in genomic technology and an increase in the number of gene-disease
associations have helped reduce the number of individuals living without a diagnosis.
Whole exome sequencing (WES) analyzes the entire human exome in an attempt to
determine if there is a molecular etiology for individuals who remain undiagnosed after
other clinical or molecular investigations. Still, WES leaves most individuals
undiagnosed, resulting in feelings of disappointment and uncertainty. Individuals who
remain undiagnosed after WES can subsequently undergo WES reanalysis later due to
improvements in bioinformatics, software updates, and an increase in known genedisease associations. This is the first study, to the investigator’s knowledge, which
investigates parental perspective of those undergoing the most current genetic testing
available. This study recruited parents of undiagnosed individuals who have completed
WES and subsequent reanalysis through the Greenwood Genetic Center to investigate
their response to and experience with WES reanalysis while on their diagnostic odyssey.
Six semi-structured interviews were conducted, recorded, and transcribed verbatim.
Transcripts were analyzed using grounded theory and assigned codes to meaningful
segments of text. Results showed most participants had lower expectations of reanalysis

1

Lucas, N., Jordon, E., Jones, J., & Corning, K. To be submitted to Journal of Genetic Counseling.
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compared to the initial WES and felt it would not lead to a diagnosis. Most participants
responded to nondiagnostic reanalysis results with feelings of disappointment and worry
about the future. However, some exhibited a difference in the degree to which they
negatively responded. Most participants recognized that reanalysis has been unhelpful for
their child but expressed willingness to contribute to science if it will assist future
individuals on a diagnostic odyssey. Despite feelings that reanalysis was unhelpful, most
participants would consider reanalysis again for their child. Considering the apparent
comprehensive nature of genomic testing, these results show there is a need to balance
hope and realistic expectations during counseling and consent of WES reanalysis. In
addition, parents desired ongoing medical support which can be offered through
reanalysis.
2.2 Introduction
Advances in genomic technology and an increase in the number of gene-disease
associations have helped reduce the number of individuals living without a diagnosis.
Receiving a medical diagnosis can be beneficial for many reasons. A diagnosis can help
direct treatment, aid in anticipatory guidance, determine prognosis, and influence family
planning (Carmichael et al., 2015). The lack of a diagnosis can have various adverse
effects for individuals and their families. This may include the inability to receive certain
medical or educational services provided and covered by insurance or the state.
Additionally, families may emotionally feel isolated, unable to connect with others living
with a similar diagnosis, or have difficulty in coping with an uncertain future
(Graungaard & Skov, 2007).
The journey and search for a diagnosis is referred to in the clinic and literature as
a “diagnostic odyssey” (Carmichael et al., 2015). Many individuals searching for a
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diagnosis have been on a diagnostic odyssey for years. A diagnostic odyssey can be
emotionally exhausting and financially costly for individuals and their families. A recent
study found that undiagnosed individuals can be spending up to $21,000 searching for a
diagnosis (Stark et al., 2017).
Genetic testing is a quickly evolving field that many undiagnosed individuals
have pursued. Whole exome sequencing (WES) first was offered clinically in 2011 and is
just one example of genetic testing that undiagnosed individuals may pursue (Atwal et
al., 2014). WES reads the entire human exome, which is the portion of all the human
genome that codes for proteins made within the body. Therefore, WES analyzes a critical
portion of the human genome.
Indications of WES include cases of undiagnosed, medically complex patients
whose medical conditions are unidentified through previous clinical or molecular
investigations. Due to cost and amount of data sequenced, WES is recommended as one
of the last steps in the search for a diagnosis (Stark et al., 2016). As WES and data
analysis become more efficient and cost effective, its use in clinical genetic testing will
become increasingly accessible. Currently, WES gives a molecular diagnosis in about 2540% of cases (Baldridge et al., 2017; Farwell et al., 2014; Lee et al., 2014; Yang et al.,
2014). Therefore, up to 75% of individuals pursuing WES remain undiagnosed.
Patients who remain undiagnosed after WES can subsequently undergo WES
reanalysis later. After a significant amount of time has passed, theoretically various
factors such as the number of gene-disease associations have improved thus increasing
the likelihood of finding a diagnosis. A database of human genes and genetic disorders
and traits, known as Online Mendelian Inheritance in Man (OMIM), increased their
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database with about 266 new gene-disease associations per year between 2004 and 2015
(Wenger et al., 2017). As variant databases grow, laboratories will have the ability to
update previous reports and variant classifications thus underscoring the importance of
reanalysis of WES results.
Although there are currently no published guidelines on WES reanalysis,
laboratories may use their own guidelines for WES reanalysis, such as waiting at least
one year between the initial test and the reanalysis (Williams et al., 2016). A recent study
found that reanalysis at a one to two-year interval could result in a 13% reanalysis
diagnostic yield (Wright et al., 2018). In other words, 13% of individuals who did not
receive a diagnostic result from their initial WES were diagnosed after reanalysis. The
increasing yearly rate of gene-disease discovery and increasing size of variant databases
in combination with recently published WES reanalysis data has validated that reanalysis
is useful in those who have not received a diagnosis from their initial WES results.
It is further necessary to explore patient, or family, perspective of those
undergoing WES and reanalysis. WES is not first-tier testing; therefore, this population
was unique and had already completed previous genetic testing. Parents feel a sense of
duty to pursue WES to find a diagnosis. Even when an individual receives a diagnosis
from WES, the condition may be rare, leaving the family with feelings of frustration and
continuing lack of anticipatory guidance (Graungaard & Skov, 2007).
Because WES analyzes much more data than most other clinical and genetic
testing options, the test can give these families hope after previous genetic testing has
been inconclusive (Rosell et al., 2016). On the other hand, the comprehensive nature of
WES may give families false hope and cause feelings of disappointment following
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nondiagnostic results (Brett et al., 2018). The dichotomy of emotions before versus after
testing calls for a balance between hope and realistic expectations.
Although there have been several studies investigating parental perspective for
those going through WES for the first time, none to the researcher’s knowledge, have
assessed the impact that WES reanalysis has on undiagnosed individuals and their
families. This study aimed to gain further insight into individuals and families who had
received a negative, or nondiagnostic, test result from their initial WES and subsequently
completed reanalysis. Compared to previous research on the topic, this qualitative study
aimed to gain more in-depth knowledge regarding family emotions experienced after
reanalysis, to understand the impact of the process and the results on the undiagnosed
individual’s care, and to obtain the family’s response to the testing experience.
Understanding factors associated with WES reanalysis may help medical
professionals specifically address the needs of individuals pursuing reanalysis and help
the families gain fulfillment and satisfaction from genetic services. Genetic counselors
and other healthcare providers help counsel, interpret, or explain reanalysis results. By
asking individuals and families about motivations, reactions, and the emotional impact of
reanalysis, this study highlighted patient and family perceptions of the value this type of
genetic testing has to offer. Identifying themes and experiences for those undergoing
reanalysis may help genetic counselors to understand the needs to be addressed for this
unique patient population. Therefore, this study aimed to provide guidance for genetics
healthcare providers working with individuals and families pursuing the recent
technology of reanalysis.
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Given that WES has been found to provide families hope before testing, it was
thought that WES reanalysis would have similar expectations preceding results. WES
reanalysis is a facet of an already complicated, non-specific test. Therefore, it was
difficult to know what their perception of and understanding behind reanalysis would be.
Most families do not receive diagnostic results from WES, and even fewer receive
diagnostic results from reanalysis. This study was expected to find frustration as a
significant emotional response to nondiagnostic reanalysis results. It was expected that
those who received a diagnosis from reanalysis would have a more positive response to
the testing than those who remained undiagnosed. This was primarily an exploratory
study, and its goal was to provide insight into a population that might benefit from
meeting with medical professionals and to highlight unique areas of concern or interest
that could be addressed by genetic counselors and other healthcare providers.
2.3 Materials and Methods
The University of South Carolina Institutional Review Board reviewed the protocol
and designated it as exempt from review in June of 2017. Greenwood Genetic Center’s
(GGC) Clinical Genomic Sequencing Program Director, Dr. Julie Jones identified eligible
participants. When WES reanalyses were completed, Dr. Jones sent a secure email to the
ordering clinicians and genetic counselors, to recruit patients to the study. Eligible
participants were recruited by phone using an original script (see Appendix A). The
recruitment process took place from August 14, 2017 until February 14, 2018. For sample
size calculation, the total number of eligible participants was provided to the primary
investigator (PI) in aggregate by GGC.

26

The inclusion criteria were as follows:


Individual, or caretaker of an individual, who has completed reanalysis of
whole exome sequencing through Greenwood Genetic Center



Individual, or caretaker of an individual, who has received a diagnostic OR
nondiagnostic reanalysis of whole exome sequencing



For individuals under the age of 18 who have completed reanalysis, their
caretaker could participate



Individual who speaks fluent English

The exclusion criteria were as follows:


Individuals under the age of 18

The phone number and name of interested participants were obtained by their
respective clinician and given to the PI through an encrypted email. Afterward, interested
participants were contacted by the PI to determine a time for the interview.
Semi-structured interviews were completed over the phone. Participation consent
was obtained verbally at the beginning of each interview phone call by the PI reading aloud
a standard script (Appendix B). Telephone interviews lasted up to 40 minutes.
Demographic variables were collected and included gender, age, ethnicity, highest level of
education attained, relationship status, location of residence, and number of children. In
addition, participants were asked if their child’s reanalysis was diagnostic or nondiagnostic
as well as when the initial WES and reanalysis was completed. GGC confirmed, or
clarified, when each WES and reanalysis was truly completed. Key topics explored for
qualitative analysis included participant understanding and expectation of reanalysis,
response to reanalysis results, and any advice for medical professionals offering reanalysis.
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Interviews were recorded on the PI’s password protected computer using
Microsoft Voice Recorder. Next, interviews were transcribed verbatim by the PI into a
Microsoft Word document. For the responses collected from interviews, grounded theory
methods were used to analyze the qualitative data. There were no preset themes for the
study’s focus. The PI and an assistant independently identified and coded apparent
themes from the participants’ responses and reported on their frequency. Kappa
coefficient was calculated to be 0.605. To address the goals of this study, themes were
identified among participant responses to compare them to previous literature published
on parental experience with WES. Quantitative data was described by counting response
types and through descriptive statistics (percentages and means). All identified themes
and representative quotes can be found in Appendix C.
2.4 Results
There were 25 total whole exome sequencing (WES) reanalyses completed by
GGC of which 23 were eligible for this study. One of the 23 eligible families had
significant psychosocial issues that their clinician and counselor felt would not lend
themselves well to participate and, therefore, were not contacted. Thus, there were 22
eligible participants for which contact was attempted by GGC clinicians and counselors
between August 2017 and February 2018. The PI received eight verbal consents and
successfully contacted six of the eight (75%). Therefore, this study successfully recruited
six of the total 22 eligible (27%). All participants completed telephone interviews. Length
of the interviews was between 14 and 38 minutes.
The sample had an age range of 22 to 45 years (average age of 34) and all were
Caucasian females. The majority were married, had between 3 and 4 children, resided in
South Carolina, and were college educated. There was a gender balance between males
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and female children. None verbally reported that their affected child had a molecular
diagnosis. One participant’s child had received a clinical diagnosis of Autism Spectrum
Disorder (ASD) after reanalysis completion. She felt that clinical diagnosis explained her
child’s full phenotype. Table 2.1 provides participant demographics.
Table 2.1 Participant demographics (N=6)
Characteristics
Gender
Age

Ethnicity
Highest level of education

Relationship status

Current residence

Number of children

Sex of affected child
Affected child has
molecular diagnosis

Response

n

(%)

Male
Female
20-29 years
30-39 years
40-49 years
50+ years
Caucasian

0
6
2
3
1
0
6

(0)
(100)
(33)
(50)
(17)
(0)
(100)

Some High School
High School
Technical Degree
Bachelor’s Degree
Master’s Degree
Married
Single/Committed
Divorced
South Carolina
Georgia
Kentucky
0-2
3-4
5+
M
F
Yes
No

1
1
1
2
1
4
1
1
4
1
1
2
4
0
3
3
0
6

(17)
(17)
(17)
(33)
(17)
(66)
(17)
(17)
(66)
(17)
(17)
(33)
(67)
(0)
(50)
(50)
(0)
(100)

On average, parents recalled expressing concern for their child’s symptoms at two
months of age with a range from birth to six months. Data provided by GGC on the
sample interviewed showed the youngest age at which initial WES results were reported
was at 6 weeks and oldest 15.5 years of age (average age of 6). The youngest that
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reanalysis results were reported in the sample interviewed was at 2.3 years and oldest
16.9 years of age (average age of 7.8). The average time between a child’s initial WES
and reanalysis was 1.75 years. All samples’ initial WES reports were issued between
2015 and 2016. All reanalyses were reported between 2016 and 2018. Individual
timelines can be visualized in Figure 2.1.

Individual Timelines (2015-2018)
6

Participant

5
Time until initial
WES report

4

Time until
reanalysis report

3
2
1
0

5

10

15

20

Age of child (Years)

Figure 2.1 Individual timelines for each participant’s child. Figure adapted
from Rosell et al., 2016.
The PI received unidentifiable WES and reanalysis results for the interviewed
sample of six. Three of the six had normal initial WES results. The other three initial
results detected variants but none explained the child’s phenotype. One child’s initial
WES results found two variants in one gene; one pathogenic and the other a variant of
uncertain clinical significance (VUS). These two variants were part of an ongoing
research study taking place outside of GGC. The study’s goal was to investigate the
effect of the two variants. The outside study had recently concluded that the two variants
detected on the child’s initial WES were responsible for the patient’s full phenotype.
Although this child now has a molecular diagnosis, the study participant and PI were
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unaware of these findings at the time of the interview therefore, this participant’s child
was undiagnosed during data collection. Individual WES and reanalysis results can be
found in Table 2.2.
Three of the reanalyses did not detect any new variants. One of the initial WES
that was negative detected a new VUS and a variant that partially explained the child’s
phenotype. This was not reported verbally to the PI by the participant during the
interview. The other two reanalyses detected new information including variants of
uncertain significance (VUSs) and a heterozygous pathogenic variant associated with
autosomal recessive disease. Neither of those two reanalyses detected variants thought to
be responsible for the child’s phenotype. Overall, half of the reanalyses gave the family
new information but none leading to a complete explanation of phenotype.
Presented below are five main themes found describing parental understanding of
reanalysis, response to, and impact of reanalysis results. Key themes found include
expectation of reanalysis, negative emotional response to results, acceptance, altruism,
and support. Subthemes are described in each section.
2.4.1 Expectation of reanalysis. Five of six participants understood why
reanalysis of initial WES data might yield a diagnosis after previous WES results had not.
One was unsure why the reanalysis was useful. Four participants explained that there
have been new advances in technology and new gene discoveries over the last few years.
Why don’t we just do this again to make sure there is nothing else, you
know. And there were some new advances in the past couple of years.
That maybe it could ...detect things that it couldn’t detect a couple years
ago. Participant 4, 5.5-year-old daughter
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Table 2.2 WES results, provided by GGC (N=6)
Case

1 hemizygous X-linked VUS

Age reanalysis Reanalysis report
report issued
8yrs (2017)
Diff. hemizygous X-linked VUS;
1 heterozygous pathogenic variant
assoc. with AR disease

2

7.6yrs (2015)

Normal

9.5yrs (2017)

Normal

3

15.5yrs (2015)

Normal

16.9yrs (2016)

1 de novo likely pathogenic variant
explaining partial phenotype;
1 VUS assoc. with AR disease

4

3yrs (2015)

2 VUS assoc. with AR
disease; 1 VUS assoc. with
XLR disease; 2 heterozygous
variants in trans in one gene
(1 pathogenic, 1 VUS)

5.5yrs (2017)

1 VUS reclassified benign

5

6wks* (2015)

Normal

2.3yrs (2017)

Normal

6

3.3yrs (2016)

1 hemizygous VUS

4.6yrs (2018)

Normal
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Initial WES report

1

Age initial WES
report issued
7yrs (2016)

*WES was completed on amniocytes
Abbreviations: Diff=different; assoc=associated; AR=autosomal recessive; XLR=X-linked recessive

Similar responses acknowledged advancements in science as the main reason for
missing anything the first time. Those responses explained reanalysis as a way to “double
check” results as opposed to advancements in technology driving reanalysis. Overall, all
but one response described that reanalysis had the ability to detect or reclassify a
previously undetected or unknown variant. One of the participants opted in to secondary
findings during the reanalysis. Participant reasons for reanalysis can be found in Figure
2.2.

Reasons for Reanalysis
4.5

Number of responses

4
3.5
3
2.5
2
1.5
1
0.5
0
Confirm nothing
was missed

Improved detection

Possibility of
reclassification

Unsure

Participant reason

Figure 2.2 Participant reason for reanalysis. Improved detection included gene discovery
and improvements in technology.
Although all but one participant noted they remained hopeful of finding a
diagnosis, some had differing levels of expectations which ranged from low to high
expectations that reanalysis would provide a diagnosis. A low level of expectation was
assigned when the participant did not expect that reanalysis would lead to a diagnosis. A
moderate level of expectation was assigned when the participant did not feel reanalysis
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would yield a diagnosis but still felt there was a chance. A high level of expectation was
assigned when the participant reported that they felt reanalysis would lead to a diagnosis.
Finally, a neutral level of expectation was assigned when the participant could not
comment either way on level of expectation. Level of expectations of each participant can
be seen in Table 2.3. One participant held high expectations due to her understanding of
reanalysis.
...because they were like, uhm, you know, we’ve made leaps and bounds
in two years and you know, hopefully something is going to come up or
not come up so we can know it’s not there, you know. I think I put even
more into it this time because it’s been two years and they’ve made a ton
of progress. Participant 2, 2-year-old daughter
Two of the participants expressed moderate levels of expectation for reanalysis. One felt
that reanalysis was an afterthought, leading to a low expectation.
Reanalysis was kind of like okay were going to do that again, no big deal. So, it
wasn’t as big of a deal. Participant 4, 5.5-year-old daughter
Two had neutral expectations, one of which was unsure about why reanalysis was
completed and the other had a similar confusion about reanalysis.
Table 2.3 Participant expectation of reanalysis

Sex of child

Age of child
at interview

Time between initial
WES and reanalysis

Expectation of reanalysis

M
F
F
F
M
M

8 years
9 years
18 years
5.5 years
2 years
4 years

1 year
2 years
1 year
2.5 years
2 years
2 years

Moderate
High
Neutral
Low
Neutral
Moderate
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Participant hope for a diagnosis changed from WES to reanalysis. One participant
recalled how expectations were different during the initial WES compared to reanalysis.
I guess I should say expectations were different. I was hoping on the first
one that we would get answers and on the second one felt more like I
didn’t expect that we would find anything. So, by that point we’ve tried
everything we can...so I see that I was really hopeful we would get
answers. Participant 6, 4-year-old son
In addition to retaining hope in the presence of lower expectations, was
the obligation to pursue testing. All but one participant would reconsider
reanalysis again for their child if it had a chance of finding a diagnosis. When
asked if they would consider reanalysis again, participants responded that they
feel they should try everything, especially if a medical professional feels it might
be beneficial. They felt a duty to complete any testing that might lead to a
diagnosis, including reanalysis. These responses expressed some degree of hope
that reanalysis may lead to diagnosis at some time. One participant who was
unsure if they would pursue reanalysis further explained her child was diagnosed
recently with ASD and felt there was no need to pursue further genetic testing.
Similarly, when participants were asked to provide advice to other
families pursuing reanalysis many emphasized the role of positivity and hope,
even if expectation of WES had decreased. Two of the participants expressed a
duty and obligation to pursue all recommended testing and to keep trying.
Keep trying, I mean that’s all you can do. Participant 2, 2-year-old
daughter
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2.4.2 Negative emotional response to results. All participants verbally stated
WES and reanalysis had not provided a diagnosis for their child. When participants were
asked to describe their reaction to the reanalysis test results, most recalled an immediate
negative emotional response to the results. The overall negative emotion associated with
these results was disappointment. Disappointment was accompanied by frustration, guilt,
and worry.
I know it’s not my fault but I feel like it’s my fault... I remember being a
little upset when I got the results back because they could say, again, you
know, that it was from me. Participant 1, 8-year-old son
Common concerns following results included worry about the life expectancy, treatment,
and recurrence risk. In this way, reanalysis elicited more questions than answers just as
the initial WES had.
Also felt like his future was really uncertain. So like some genetic
disorders you find out and like they have a low life expectancy. They’ll
never, you know...and like knowing that that was possible, that we had no
way of knowing, felt really disconcerting. And it probably took us a few
months to say out loud, “will he ever leave our house? Or will he be an
adult needing to be cared for?” ...sort of what we have found is that there’s
more questions than answers. Participant 6, four-year-old son
A subtheme noted was a difference in the degree to which a negative response
was elicited compared to the initial WES results. Most participants did not have as much
of a negative emotional response following reanalysis results compared to the initial
WES.
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I felt like we got the big blow of that there is something happening the
first time. So that like scariness of okay this is real, happened the first
time. And so the second time I didn’t have that same surprise of like okay
there is something going on. Before I didn’t think there was. Participant 6,
4-year-old son
Participants felt that they had been through this testing before; therefore, receiving
negative, nondiagnostic results was not as disappointing as the first WES results.
On the other hand, one participant felt she had been given false hope and,
therefore, had an enhanced negative emotional response of frustration.
Frustrated! Because we haven’t really asked for any of this stuff...it’s not my fault
that the geneticists haven’t caught up yet, to find out what she has to give it a
name. Participant 2, 2-year-old daughter
Two participants noted that lack of financial burden affected how they perceived
this testing. It is important to note that GGC did not bill insurance or the patient
for reanalysis. Therefore, these participants did not have a financial burden from
reanalysis. Although cost associated with the initial WES was not a focus of this
study nor discussed during interviews, participants mentioned that finances would
affect decision-making during the course of WES and reanalysis. One admitted
that if they had paid for reanalysis themselves, they would not make the test a
priority because they do not have much faith in the test to find a diagnosis after
negative initial and reanalysis results.
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I don’t think we would have run the reanalysis if…I know we
wouldn’t have run the reanalysis if there had been a financial piece
on us. Participant 6, 4-year-old son
The others knew that they would have been even more disappointed with
the nondiagnostic results but knew they would pursue reanalysis again if the
doctors ever felt reanalysis would be helpful.
If I had paid the big bucks, I probably would have been very
disappointed ...you still feel like you threw your money away. But
it is worth it, ‘cause you want to know. Participant 4, 5.5-year-old
daughter
Furthermore, GGC does not bill for reanalysis, therefore none of the participants
had paid for reanalysis.
2.4.3 Acceptance. Present in all the interviews was a theme of acceptance. At
some point on their diagnostic odyssey, these families have accepted they will likely not
receive a reason or name for their child’s diagnosis. Because these families have been
undiagnosed for years, they have been learning to cope with uncertainty. Results from
reanalysis are coming at a time when they have already dealt with the initial shock that
their child will be living with a medical condition for the rest of their lives. In this way
they have become resilient to disappointing test results.
It’s just been a long 18-year journey with her. And I just pretty much went
on ahead and accepted her for the way she was. And how she was going to
be. And I just took it day by day with her…I don’t get my hopes up for
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nothing, because I’ve learned that when she was a baby. So I just take it as
it comes. Participant 3, 18-year-old daughter
By the time of reanalysis they have accepted this is how their child will be and
shifted the majority of their focus on treating their child, rather than fixating on a
diagnosis.
‘Cause, you know, it’s like the first time you’re really talking about like
there’s definitely something wrong with my kid, like it’s a fact and you’re
still accepting it. I think by the time exon sequencing results come in we’d
been dealing with this for a couple of years. And we kind of hardened, and
kind of like much more like not surprised by stuff. Participant 4, 5.5-yearold daughter
Although participants exhibited acceptance of not finding a diagnosis, participants
noted that staying positive is how they cope with nondiagnostic results.
Well I’m trying to look at it in a positive way, and not findings some
answers have been a good thing... So I’m trying to look at it that way, that
no answer is a good answer... I’m still staying positive on it...we’re just
going to keep doing what we’re doing. Hopefully one day we’ll figure it
all out. Participant 1, 8-year-old son
2.4.4 Altruism. All participants expressed that WES and reanalysis has been
unhelpful for their own child. Although the testing was felt to be unhelpful, none
regretted completing the testing. Half expressed if the testing was not hurting their child
and data might help future families then it was worth it.
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I think eventually if it doesn’t help [our daughter] it’ll help someone else
...if it keeps one other person, eventually down the road, from having this
then, or from having to deal with it without a name, then it’s worth it.
Participant 2, 9-year-old daughter
Some understood that this testing may aid in new discoveries which was
enough reason to pursue testing.
We both sort of got to a place of like I mean that’s fine we can keep
digging in for science sake but it doesn’t seem to be really helping [our
son]. Participant 6, 4-year-old son
2.4.5 Support. When asked what was helpful during WES reanalysis, participants
expressed the important of immediate and ongoing communication from the genetics
community. Immediate support was desired in the form of clear communication and time
spent explaining the test during appointments. Three of the participants felt their genetic
counselor and geneticist clearly communicated why reanalysis might be beneficial. When
families felt the medical professionals would take the time to explain WES and
reanalysis, participants noted an appreciation for honesty and realistic expectations.
I think the biggest thing is being clear up front, which they were. Is that
you may not get anything out of this. You still may not have an answer.
Participant 4, 5.5-year-old-daughter
Not only was immediate support during appointments important but ongoing
support was desired through email and telephone. One participant felt strongly about her
genetic counselor’s ongoing availability to answer questions.
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And I could call 50 times and she would still answer the questions. And I
think that’s really big because sometimes when we come in and we talk to
you guys and you tell us all this stuff and we’re just trying to process that
our kid has something and it might not be that day that we realize we have
a question. We need to know that we can call back and ask those questions
and you’re not going to be upset and that you’re going to answer them.
Participant 2, 9-year-old daughter
2.5 Discussion
The population interviewed is unique because these families have pursued many
clinical and genetic tests which have not led to a diagnosis for their child. When one of
the most comprehensive genetic tests available such as WES reanalysis does not lead to a
diagnosis for their child, parents may find themselves with more questions than answers.
This poses new challenges not only for families undergoing reanalysis but also for
medical professionals offering reanalysis. Similar to previous studies investigating
parental experiences with WES, responses supported that reanalysis can give families
hope of findings a diagnosis (Rosell et al., 2016). In addition, responses supported that a
negative emotional response follows nondiagnostic test results (Brett et al, 2018;
Krabbenborg et al., 2016).
This is the first study to identify parental understanding, response to, and impact
of WES reanalysis that the principal investigator is aware of. Although this study was
exploratory and completed on a small sample, it provides insight on essential aspects
including psychosocial implications and parental experience that should be taken into
consideration when offering reanalysis to individuals and families.
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2.5.1 Practice implications. Most participants had some level of understanding
as to why reanalysis might lead to a diagnosis after previous WES had not. In accordance
with a previous study investigating parental understanding of initial WES, this study
indicated that this sample received effective pre-test counseling that explained reanalysis
(Tolusso et al., 2016). Responses also showed parental understanding of reanalysis likely
influenced their expectation that reanalysis would lead to a diagnosis. It appeared that
those who appropriately understood that reanalysis might not lead to a diagnosed reported
a low to moderate expectation. For the majority of participants, their expectations of
testing were not higher than their initial WES.
On the other hand, one participant reported a high expectation due to her
understanding that there have been numerous advances made within the last few years.
She had a similar, if not higher, level of expectation to the initial WES. This perception
of reanalysis led to a feeling of false hope. Brett and colleagues (2018) recently identified
balancing hope and expectations during the course of genomic testing being a significant
counseling challenge. These results further emphasize the importance of balancing hope
with realistic expectations while counseling these families. Being honest with parents
during pre-test counseling is equally important as instilling hope. One suggestion might
be to present the diagnostic yield of reanalysis being approximately 10% based on recent
research (Wenger et al., 2017; Wright et al., 2018). In this way one can inform them that
reanalysis may not lead to a diagnosis and can let them develop an informed perception
of reanalysis.
Similar to initial WES results, when reanalysis did not lead to a diagnosis there
was an immediate negative emotional response (Brett et al., 2018; Graungaard & Skov,
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2007). Although the type of emotional response did not change from the initial WES to
the reanalysis, the degree to which the results elicited a negative response did change.
Most participants expressed there was less of a negative emotional response following
reanalysis than the initial WES. There were no new emotions identified. Participants
likely had a different degree of response because they had previously experienced
nondiagnostic results from this testing and were prepared to receive similar results.
Although these participants seem to already possess the ability to cope with these types of
results, it is still necessary to prepare them for nondiagnostic reanalysis results. This
should be done to avoid exacerbated negative feelings that follow false hope.
Furthermore, the degree to which parents negatively responded differed from their
initial testing depending on their perception of reanalysis. This was observed in the
participant who expressed high expectations of reanalysis. When holding high
expectations of reanalysis, she experienced a heighted negative emotional response to
reanalysis. This further bolsters the need to give realistic expectations of reanalysis.
Although one cannot predict how a parent will respond to negative results, medical
professionals should consider how they can present reanalysis to help families properly
respond to nondiagnostic results.
A second aspect found to influence the response to reanalysis results was where
the parents were on the timeline of their diagnostic odyssey. At some point these families
have accepted they may not find a diagnosis for their child’s condition. Acceptance may
come at different times for different families but by the time they are pursuing reanalysis
they have dealt with disappointment from previous experiences with testing. Through
these disappointing experiences, they have learned to accept an uncertain future.
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Although these families have accepted an uncertain future, pursuing reanalysis can
remind them that the genetic community has not given up on finding a diagnosis for their
child.
While many participants felt reanalysis was unhelpful for their child this study
found that most would consider reanalysis again for various reasons. Like Rosell and
colleagues (2016), this study found that parents feel an obligation to try everything
possible that could help diagnose their child’s condition. The hope for a diagnosis
outweighed their negative response to the results. A second reason for pursuing
reanalysis was a desire to help families in the future. This indicated altruism and a desire
to help others even when testing has been unhelpful for themselves. Despite a negative
emotional response, participants were motivated by the possibility to help future families
in similar situations to them. It may be beneficial for all ordering providers to explain
how their child’s reanalysis may aid in future discoveries and help future families receive
a diagnosis. This may be through reanalysis or offering data be used in research.
Interestingly, a reason participants noted that they might not pursue reanalysis
again is if there was a financial burden. None of the participants paid out-of-pocket for
reanalysis and, therefore, there was no cost burden to outweigh the possible benefits of
testing. Some mentioned that if they had to pay they would have struggled more with the
decision to pursue reanalysis. With a diagnostic yield of 13%, these families may not feel
reanalysis would be worth it if they had to pay. Although GGC does not currently charge
for reanalysis, this may be pertinent for families completing reanalysis through other labs
as some will charge for reanalysis or have differing billing policies surrounding
reanalysis. This might change the extent to which these families feel reanalysis is an
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option. In addition, it is possible families would have greater expectations or negative
emotional responses if they are financially, not only emotionally, invested in the testing.
Importantly, participants noted an appreciation for immediate and ongoing
support during their experience with reanalysis. Immediate support was desired during
appointments by medical professionals taking the time to explain reanalysis and identify
risks versus benefits. This is similar to any pre-test counseling offered to these families.
Ongoing support was appreciated through knowing a medical professional was available
for these families to reach out to when needed. In this study, a genetic counselor was the
medical professional managing their testing and fielding questions from these
participants. It was important that these families knew they could call or email to ask any
medical question, as these questions frequently arose after appointment times. After
experiencing care with other specialties, these participants felt genetics understood the
need for immediate and ongoing support. It was comforting to the families that a medical
professional recognized the need for support outside of their appointment. This ongoing
support seemed to reduce some emotional burden found to be associated with being
undiagnosed.
Different from any other testing available, reanalysis itself is a form of ongoing
support for these families after comprehensive WES results have not led to a diagnosis.
The test lets families know there may be something more to offer them in the future. It
acts as a reminder that their care team has not forgotten about them. Results indicated that
although they remained hopeful for a diagnosis, they did not feel a diagnosis was
essential at this point in their child’s life. At this point in their odysseys most had
accepted that they will not receive a name for their child’s condition. Although the results
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from reanalysis are important when yielding actionable results, these families may be
best served by the support they feel from the medical community through reanalysis.
2.5.2 Study limitations. Several factors may have influenced these results. First,
the study had a small sample size that were eligible through one institution, GGC. GGC
is one lab of many who offers WES and reanalysis. All labs have unique WES and
reanalysis procedures, billing policies, and diagnostic yields. As discussed previously,
financial burden may largely influence the expectation and response to reanalysis results.
Surveying a sample that has completed reanalysis through a different lab may yield
different responses. Similarly, all reanalyses were offered by geneticists and genetic
counselors employed by GGC. Therefore, pre-test and case management is likely similar
for this entire sample. In reality, many different geneticists and genetic counselors are
offering reanalysis; therefore, those pursing reanalysis may have different experiences
than this sample. All these factors, including the small sample successfully recruited,
makes these results difficult to generalize to all who have completed reanalysis. Finally,
this study did not gather responses from reanalysis that resulted in a diagnosis; therefore,
data were unable to establish differences between diagnostic and nondiagnostic reanalysis
results.
2.5.3 Future research. A study including more participants, with reanalysis
ordered from different institutions, and through different laboratories would be
worthwhile as it would allow for greater insight and generalizability of results. Similarly,
collecting responses from families who have received a diagnosis through reanalysis to
compare nondiagnostic and diagnostic reanalysis experiences would be helpful. Based on
responses gathered in this study, it would also be useful to survey the role of financial
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burden of reanalysis. Finally, it would be interesting to evaluate counselor presentation
versus family perception of reanalysis to assess what patients are being told about
reanalysis compared to what they are truly retaining.
2.6 Conclusions
Whole exome sequencing and subsequent reanalysis is one of the most
comprehensive tests that can be offered to individuals who are living undiagnosed with
complex conditions. Families of those living undiagnosed can be accompanied by
adverse emotions including uncertainty, worry, and feelings of isolation. Due to an
uncertain future and feelings of isolation, support for these families is essential. Genetics
is a unique facet of healthcare that interact with these families. Genetic counselors and
other genetics professionals are in a pivotal role to offer immediate and ongoing support
to the undiagnosed population. Although these families may have accepted that they will
not find a diagnosis, they should not be forgotten. From this research it is important to
recognize that these families see reanalysis as a form of ongoing support.
Despite negative emotional responses to initial WES results, the hope for a
diagnosis was still present enough to pursue testing such as reanalysis. Most of the
participants noted that they did not have as high of expectations for reanalysis to lead to a
diagnosis as they did the initial WES. These families also recognized that reanalysis may
not be helpful for their child but were willing to complete reanalysis with the idea the
data may help future families. These results emphasized a need to balance parental hope
and realistic expectations of reanalysis. Participants appreciated honesty regarding
reanalysis. Specifically informing parents that reanalysis has a relatively low diagnostic
yield may help mitigate negative responses to nondiagnostic results.
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Although this study cannot be generalized to all completing reanalysis, it provides
preliminary insight into parental experiences with reanalysis. As more WES tests are
completed, reanalysis will become more frequent. Knowing how to navigate complex
factors such as parental emotions and questions regarding reanalysis is key to providing
these families with the support they need.
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Chapter 3: Conclusions
Whole exome sequencing and reanalysis is one of the most comprehensive tests
that can be offered to individuals who are living undiagnosed with complex conditions.
Families of those living undiagnosed can be accompanied by adverse emotions including
uncertainty, worry, and feelings of isolation. Due to an uncertain future and feelings of
isolation, support for these families is essential. Genetics is a unique facet of healthcare
that interact with these families. Genetic counselors and other genetics professionals are
in a pivotal role to offer immediate and ongoing support to the undiagnosed population.
Although these families may have accepted that they will not find a diagnosis, they
should not be forgotten. From this research it is important to recognize that these families
see reanalysis as a form of ongoing support.
Despite negative emotional responses to initial WES results, the hope for a
diagnosis was still present enough to pursue testing such as reanalysis. These results
emphasized a need to balance parental hope and realistic expectations of reanalysis.
Participants appreciated honesty regarding reanalysis. Although families may experience
a negative emotional response to nondiagnostic reanalysis results similar to that of initial
WES, they likely will not feel the emotional response to the same extent felt after the
initial results. Specifically informing parents that reanalysis has a relatively low
diagnostic yield up to 13% may help mitigate negative responses to nondiagnostic results.
Interestingly, these families also recognized that reanalysis may not be helpful for
their child but awere willing to complete reanalysis with the idea the data may help future
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families. Providers can inform parents how their child’s reanalysis data may be used in
research and subsequently help future families.
Although this study cannot be generalized to all completing reanalysis, it provides
preliminary insight into parental experiences with reanalysis. As more WES tests are
completed, reanalysis will become more frequent. Knowing how to navigate complex
factors such as parental emotions and questions regarding reanalysis is key to providing
these families with the support they need.
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Appendix A – Consent completed by GGC healthcare provider
You are agreeing to be contacted by Nicole Larsen, a genetic counseling graduate
student, with the interest in participating in a school research project. Your phone number
and name will be given to Nicole Larsen upon consent. Nicole will contact you to set up a
time for a phone interview. Your participation in this project is voluntary. Consent to
participate will be completed upon the beginning of the interview phone call.

Name of clinician or genetic counselor obtaining consent: ____________

Name of interested participant: _____________

Phone number of interested participant: _____________

Date and time of consent: ___________

Upon consent, please send this form in an encrypted to Nicole Larsen at
Nicole.larsen@uscmed.sc.ed
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Appendix B – Participant consent completed during interview
Consent statement
You are agreeing to participate in a telephone interview as a part of a genetic counseling
graduate school research project. This interview will last approximately 45 minutes to 1
hour. Your participation in this project is voluntary. You may withdraw from the study at
any time. If at any time there is a question you are not comfortable answering, please let
me know and we can proceed on to the next question. While no direct benefit may be
observed, this study may provide future benefit to others pursuing WES reanalysis and
medical professionals working with them. The risk for participating in this study are
minimal.

With your consent, this conversation will be recorded and transcribed. All responses
gathered from the interviews will be kept anonymous and confidential. If a quotation is
used from this interview, all identifying information will be removed and you will be
assigned an alternative name.

If you have any questions regarding this research, you may contact either myself or my
faculty advisor, Emily Jordon, MS, CGC. If you have any questions about your rights as
a participant, you may contact the Office of Research Compliance at the University of
South Carolina at (803)777-7095.

Do you consent to this research study? Date: _______ Time: _____
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Appendix C – Themes
Table C.1 Overall themes
Theme

Subtheme

Expectation of reanalysis

Understanding of reanalysis, hope for a
diagnosis, obligation
Disappointment, worry, guilt, degree of
response elicited

Negative emotional response to results
Acceptance

Uncertainty, time spent on diagnostic odyssey

Altruism

Future families, aiding in gene discovery

Support

Immediate and ongoing communication,
availability
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Table C.2 Themes with representative quotes
Theme

Subtheme

Example

Expectation of
reanalysis

Understanding of
reanalysis

“Yeah there is always something new coming up so...everybody is always making a
breakthrough on something.” Participant 3
“I guess they just wanted to make sure they wasn’t missing anything. I guess, I don’t
know.” Participant 5

Hope

“I was still just hopeful but more patient this time.” Participant 1
“I was hoping on the first one that we would get answers and on the second one felt
more like I didn’t expect that we would find anything.” Participant 6

Obligation
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Negative emotional
response to results

Disappointment

“[we would consider reanalysis] if they ever felt like it would be worth it for them to
reanalyze, or it would be help.” Participant 2
“...hoping that there was one magic bullet that was going to explain everything...and
there isn’t. So just disappointment with that. Participant 6
“What are you supposed to do if you can’t tell somebody what’s wrong...it’s been
very heartbreaking to see that and not put a name on it.” Participant 2

Worry

“My reaction was like “that’s fine but what do we do from here?” Participant 6
“Not that I ever thought we’d get a diagnosis and be like “oh let’s fix her.” But more
to be able to say, “Okay, this is what she has, let’s looks at other people with the same
condition. What is their life expectancy, what other organ systems get involved?” You
know, what are some things that come up in the future?” Participant 4

Guilt

“Seeing that something came from me that I could see potentially in him was a little
bit scary to see.” Participant 6

Degree of response

Acceptance

Uncertainty

Time spent on odyssey
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Altruism

Future Families

“It really didn’t bother me, because it’s just been a long 18-year journey with her.
And I just pretty much went on ahead and accepted her for the way she was.”
Participant 3
“I think we are much more resistant. By the time we had got the results, we had kind
of weren’t as impacted by things as we used to be.” Participant 4
“…but if it keeps one other person, eventually down the road, from having this then,
or from having to deal with it without a name, then it’s worth it.” Participant 2

Immediate

“They’re constantly finding out new things. You know, that trying again is never
really a bad thing. Even if you’ve done it once and found nothing. You can do it again
and find more information.” Participant 1
“I appreciate that in every appointment I feel like they’ve taken a lot of time with us.
And that was really helpful because it is really heavy information and...they’ve
always done a really good job at slowing it down. And explaining to us, without
talking down to us.” Participant 6

Ongoing

“Trust that everyone has your child’s best interest in mind, even if it’s information
that’s hard to hear.” Participant 6

Gene Discovery

Support

“A little disappointment, but I kind of knew a little bit going into it that. Kind of went
into it knowing that it may not give us an answer. So I think we’d already come
prepared for that. So a little disappointment but also expecting it at the same time.”
Participant 4
“I think some days I would want to know this is the path, even it’s the worse news
possible.... but when he’s progressing I don’t want that at all. I’m like “He can do
anything! We’re totally good.” But when it feels stale like when he’s not progressing
or when we just have more concerns than we have answers then yes. I just would
rather just have answers even if it’s worse case scenario.” Participant 6

